CN112578122B - Application of reagent for detecting content of calprotectin in preparation of teratospermia screening kit - Google Patents

Application of reagent for detecting content of calprotectin in preparation of teratospermia screening kit Download PDF

Info

Publication number
CN112578122B
CN112578122B CN202011037290.9A CN202011037290A CN112578122B CN 112578122 B CN112578122 B CN 112578122B CN 202011037290 A CN202011037290 A CN 202011037290A CN 112578122 B CN112578122 B CN 112578122B
Authority
CN
China
Prior art keywords
calprotectin
teratospermia
reagent
detection
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011037290.9A
Other languages
Chinese (zh)
Other versions
CN112578122A (en
Inventor
陆华
张琦
刘芊辰
廖睿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu University of Traditional Chinese Medicine
Original Assignee
Chengdu University of Traditional Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu University of Traditional Chinese Medicine filed Critical Chengdu University of Traditional Chinese Medicine
Publication of CN112578122A publication Critical patent/CN112578122A/en
Application granted granted Critical
Publication of CN112578122B publication Critical patent/CN112578122B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides application of a reagent for detecting the content of calprotectin (calprotectin) in excrement in preparing a teratospermia screening kit, belonging to the field of disease detection kits. According to the invention, the content of the calprotectin in the feces of different people is detected, the association between the content and the teratospermia is obvious, and the kit is developed by virtue of the principle, so that the teratospermia can be screened quickly and noninvasively, and the application prospect is good.

Description

Application of reagent for detecting content of calprotectin in preparation of teratospermia screening kit
Technical Field
The invention belongs to the field of disease screening kits.
Background
Calprotectin was first isolated from neutrophils by Fagerhol in 1980 and named L1 protein, after which it was named for its structural calcium-containing and antimicrobial properties, which has been known for 39 years to date. Wilkinson et al further confirmed that these proteins have the structural characteristics of the S-100 protein in 1988 based on the antigenic characteristics, also designated calgranulin, Dorin and Freemont et al, later designated calprotectin as a multifunctional and calbindin protein.
Calprotectin is a heterodimeric complex consisting of S100A8 and S100a9 in the S100 calbindin family, a calcium-zinc binding protein from neutrophils and macrophages, detectable in serum, body fluids or feces, has been identified as a marker of IBD in inflammatory bowel disease, and elevated calprotectin (S100A8/S100a9) levels are currently detectable in inflammatory, tumor cell and cancer populations.
Research shows that the detection of the content of calprotectin in excrement can be used for diagnosing ulcerative colitis and Crohn's disease.
However, no relationship between teratospermia and calprotectin exists at present, and no relationship between teratospermia and calprotectin (FC) in feces exists.
Disclosure of Invention
The invention aims to provide application of a reagent for detecting the content of calprotectin in preparation of a teratospermia screening kit and a novel teratospermia screening kit.
The technical scheme of the invention comprises the following steps:
use of a reagent for detecting calprotectin in feces in the preparation of a teratospermia screening kit.
As for the aforementioned use, the reagent for detecting calprotectin in feces is: a reagent for immunohistochemical detection, a reagent for Western Blot detection, a reagent for colloidal gold detection or a reagent for ELISA detection.
The reagent also includes a protein purification reagent for use as previously described.
As for the use described above, if the kit detects a greater calprotectin content in the faeces of a male subject than in a normal male, then the male subject is at a higher risk of developing teratospermia.
A teratospermia screening kit, which comprises a reagent for detecting calprotectin in excrement.
As with the kit described above, the reagents for detecting calprotectin in feces are: a reagent for immunohistochemical detection, a reagent for Western Blot detection, a reagent for colloidal gold detection or a reagent for ELISA detection.
Such as the aforementioned kit, which further comprises a protein purification reagent.
As with the kit described above, if the kit detects that the calprotectin content in the feces of the male subject is higher than that of the normal male, the male subject is at high risk of teratospermia.
According to the invention, the content of the calprotectin in the feces of different people is detected, the association between the content and the teratospermia is obvious, and the kit is developed by virtue of the principle, so that the teratospermia can be screened quickly and noninvasively, and the application prospect is good.
Obviously, many modifications, substitutions, and variations are possible in light of the above teachings of the invention, without departing from the basic technical spirit of the invention, as defined by the following claims.
The present invention will be described in further detail with reference to the following examples. This should not be understood as limiting the scope of the above-described subject matter of the present invention to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Drawings
FIG. 1: counting distribution intervals of the content of the calprotectin in the patients with various teratospermia.
In the drawings, FC means calprotectin.
Detailed Description
Example 1 screening kits (ELISA) of the invention
1. Composition of
(1) Pre-coating a plate: ninety-six well plates coated with anti-human calprotectin rabbit lgG antibody on the inner wall and bottom of the wells.
(2) Enzyme-labeled antibody: (30-fold concentration) HRP-labeled anti-human calprotectin rabbit IgG antibody.
(3) And (3) standard substance: calprotectin.
(4) Buffer solution: PBS containing 1% BSA, 0.05% tween 20.
(5) Color developing agent: TMB substrate solution.
(6) Stopping liquid: 1N sulfuric acid.
2. Sample preparation
(1) Collecting a sample by using a special sample sampling adhesive device, and discharging excrement in the center of the unfolded adhesive device, wherein the excrement cannot be stained with pollutants such as urine, blood, toilet water, toilet paper and the like;
(2) inserting a sampling rod into the excrement sample, then putting the sampling rod back into an excrement sampling tube filled with sample diluent, screwing and shaking uniformly, and repeating the actions for 3 times;
(3) sampling at a plurality of different points of the same stool sample each time, wherein the total sampling amount is about 50mg (similar to the size of a match head);
(4) screwing the sampling tube and shaking uniformly for later use;
(5) if the patient with diarrhea absorbs the thin excrement by a disposable suction tube, about 100uL (3 drops) of the thin excrement is collected into an excrement sampling tube, the thin excrement is fully shaken up for standby, and the detection is carried out as soon as possible.
3. Use of
(1) Adding 0.1mL of sample (standard product) into the pre-coated plate hole, incubating for 30min at 37 ℃, pouring off liquid in the hole, beating for 3 times, and reducing liquid adhesion;
(2) add 0.15mL buffer to wash proteins not bound to pre-coated plate, repeat 5 times;
(3) adding 0.1mL of enzyme-labeled antibody, incubating for 30min at 37 ℃, pouring off the enzyme-labeled antibody, and adding 0.15mL of buffer solution for washing for 5 times;
(4) adding 0.1mL of color developing agent, and incubating for 10min at 37 ℃;
(5) adding 0.05mL of stop solution;
(6) and (4) judging a result: the color depth is observed by naked eyes, and the deeper the color is, the stronger the positive degree is; or measuring the OD (450 nm).
The standard curve can be prepared by the steps of diluting the standard substance with gradient in advance, and the concentration of the sample is adjusted when the sample is formally detected so that the concentration falls in a linear interval (a curve of the concentration and the OD value).
The screening kit can also be prepared by the following method:
and (3) replacing the corresponding protein standard in any commercial protein detection kit with a calprotectin solution, and replacing the antibody with an anti-calprotectin antibody.
Example 2 relationship between teratospermia and the content of calprotectin (FC)
The inventors carried out calprotectin detection (using calprotectin detection kit (colloidal gold method) of Xiamen, Zhengzhi, GmbH, Japan Biotech Co., Ltd.) on 49 patients with teratospermia (normal sperm rate < 4%) who were treated at an outpatient clinic of Chengdu TCM university Hospital at 2019.06-2020.09.
The detection method comprises the following steps:
1. patient pre-test preparation
(1) For the first detection, a patient needs to collect a detection sample before taking medicines and clystering;
(2) the patient needs to be checked and sampled at least 24 hours after stopping taking the medicine;
(3) the diet 24 hours before sampling is preferably similar to that of the ordinary diet, so that overeating or taking of excessive spicy and pungent foods is avoided, and drinking is forbidden;
(4) the patient can not stay up night before sampling (the sleeping time is guaranteed to be more than or equal to 6 hours);
(5) during menstruation, sampling is not suitable;
(6) if the condition allows the feces sample of the first defecation of the patient in the early morning to be collected as much as possible for detection;
(7) patients who cannot be sampled according to the sampling requirements are not suitable for testing.
2. Sample collection and detection
(1) Collecting a sample by using a special sample sampling adhesive device, and discharging excrement in the center of the unfolded adhesive device, wherein the excrement cannot be stained with pollutants such as urine, blood, toilet water, toilet paper and the like;
(2) inserting a sampling rod into the excrement sample, then putting the sampling rod back into an excrement sampling tube filled with sample diluent, screwing and shaking uniformly, and repeating the actions for 3 times;
(3) sampling at a plurality of different points of the same stool sample each time, wherein the total sampling amount is about 50mg (similar to the size of a match head);
(4) screwing the sampling tube and shaking uniformly for later use;
(5) if a patient with diarrhea absorbs the thin excrement by using a disposable suction tube, collecting about 100uL (3 drops) of the thin excrement into an excrement sampling tube, fully shaking the thin excrement into a uniform state for standby, and detecting as soon as possible;
(6) taking out the matched detection card from the aluminum foil bag, marking and horizontally placing the detection card on a horizontal workbench;
(7) unscrewing a cap of the sampling tube, discarding two drops of diluted samples at the head, slowly and vertically dripping 100uL (3 drops) of bubble-free diluted samples at the center of a sample adding hole of a detection card, inserting the detection card into a calprotectin detector, and starting timing;
(8) the result is interpreted within 10-15min, and the test result is invalid after 15 min.
The results show that: the FC content is more than or equal to 15ug/g as positive (FC positive). 49 teratospermia male patients with the average age of 38.486 + -8.224 years and 6 patients with FC <15ug/g account for 12.24%; 43 cases of FC more than or equal to 15ug/g account for 93.47% (Table 1), 11 cases of FC more than or equal to 60ug/g account for 22.448%, the highest value reaches 730ug/g, and the positive case has a calcium defense value of 88.864 +/-70.739 ug/g (Table 2). Wherein the increased FC value is mainly concentrated in the interval of 60-240ug/g (as shown in figure 1), and accounts for 30 cases in total, and accounts for 61.224 percent. The mean age was 35.355 + -8.122 years, 24 FC <15ug/g accounted for 75%, 8 FC > 15ug/g, calcium guard (23.813 + -8.306) ug/g in positive individuals (Table 2), and the difference in FC positive values between the two groups was statistically significant (P < 0.05) in the 32 healthy male controls (males excluding teratospermia).
TABLE 1 Male teratospermia FC positivity (FC content ≥ 15ug/g)
Figure BDA0002704805610000041
Figure BDA0002704805610000051
TABLE 2 comparison of FC-Positive male teratospermia with healthy males
Figure BDA0002704805610000052
From global considerations (including FC <15ug/g and FC ≧ 15ug/g), both healthy men and teratospermia patients will have FC means that are lower due to the FC-negative (FC <15ug/g) segment of data. However, the FC <15ug/g ratio of healthy men is obviously larger than that of teratospermia patients, the FC mean value of healthy men is pulled lower in the FC negative part data, and the difference between FC values of healthy men and teratospermia patients is larger. It can be seen that the FC values of healthy men and patients with teratospermia are very different from each other globally, and that the FC values can distinguish healthy men from patients with teratospermia.
This example shows that patients with teratospermia have significantly higher FC content than healthy men, and men with high FC content are at higher risk of developing teratospermia.
In conclusion, the teratospermia is related to calprotectin in the excrement, and the kit disclosed by the invention can be used for rapidly screening the teratospermia by detecting the calprotectin in the excrement sample.

Claims (4)

1. Use of a reagent for detecting calprotectin in feces in the preparation of a teratospermia screening kit.
2. The use of claim 1, wherein the agent for detecting calprotectin in faeces is: a reagent for immunohistochemical detection, a reagent for Western Blot detection, a reagent for colloidal gold detection or a reagent for ELISA detection.
3. Use according to claim 1, characterized in that: the reagents also include protein purification reagents.
4. Use according to any one of claims 1 to 3 wherein the male subject is at increased risk of teratospermia if the kit detects a greater calprotectin content in the faeces than in a normal male subject.
CN202011037290.9A 2019-09-27 2020-09-27 Application of reagent for detecting content of calprotectin in preparation of teratospermia screening kit Active CN112578122B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019109320366 2019-09-27
CN201910932036 2019-09-27

Publications (2)

Publication Number Publication Date
CN112578122A CN112578122A (en) 2021-03-30
CN112578122B true CN112578122B (en) 2022-08-02

Family

ID=75119796

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011037290.9A Active CN112578122B (en) 2019-09-27 2020-09-27 Application of reagent for detecting content of calprotectin in preparation of teratospermia screening kit

Country Status (2)

Country Link
CN (1) CN112578122B (en)
WO (1) WO2021057987A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113584148A (en) * 2021-06-30 2021-11-02 吉林大学 Specific marker screening method for azoospermia and severe oligospermia detection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101213454A (en) * 2005-05-21 2008-07-02 蛋白质系统股份公司 Annexin for cancer risk assessment
WO2010062663A1 (en) * 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
CN102639710A (en) * 2009-07-20 2012-08-15 基因泰克公司 Gene expression markers for crohn's disease
CN103207274A (en) * 2013-04-28 2013-07-17 成都中医药大学 Screening kit for seventh chromosome abnormality diseases of fetus
CN105842459A (en) * 2016-03-24 2016-08-10 泰州海路生物技术有限公司 Immuno-chromatography kit for quickly and quantitatively detecting calprotectin in excrement
CN110208544A (en) * 2019-06-20 2019-09-06 南方医科大学深圳医院 A kind of excrement Test paper and kit

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013507928A (en) * 2009-10-15 2013-03-07 アボット・ラボラトリーズ Dual variable domain immunoglobulins and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101213454A (en) * 2005-05-21 2008-07-02 蛋白质系统股份公司 Annexin for cancer risk assessment
WO2010062663A1 (en) * 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
CN102639710A (en) * 2009-07-20 2012-08-15 基因泰克公司 Gene expression markers for crohn's disease
CN103207274A (en) * 2013-04-28 2013-07-17 成都中医药大学 Screening kit for seventh chromosome abnormality diseases of fetus
CN105842459A (en) * 2016-03-24 2016-08-10 泰州海路生物技术有限公司 Immuno-chromatography kit for quickly and quantitatively detecting calprotectin in excrement
CN110208544A (en) * 2019-06-20 2019-09-06 南方医科大学深圳医院 A kind of excrement Test paper and kit

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
绵羊生殖道提取物生物活性物质检测;陈琛等;《中国抗生素杂志》;20100225(第02期);第156-159页 *

Also Published As

Publication number Publication date
CN112578122A (en) 2021-03-30
WO2021057987A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
CN101036055B (en) Detection of elevated levels of Her-2/neu protein on circulating cancer cells and treatment
CN104246502B (en) Device for determining at least one analyte that can be contained in a liquid sample
JP2020519906A (en) Method for measuring calcium-binding protein S100 family member by immunoturbidimetric method
CN112578122B (en) Application of reagent for detecting content of calprotectin in preparation of teratospermia screening kit
JP2004530110A (en) Ovarian storage urine assay
Salman Detection of Blastocystis hominis among peoples in Kirkuk Province using ELISA and direct microscopy
CN208537564U (en) A kind of A rotavirus/Adenovirus Antigen detection kit
CN206523509U (en) A kind of stool sampling and detection integrated apparatus of occulting blood
CN112578123B (en) Application of reagent for detecting content of calprotectin in preparation of uterine lesion screening kit
CN112578125B (en) Application of reagent for detecting content of calprotectin in preparation of ovarian lesion screening kit
CN112578124A (en) Application of reagent for detecting content of calprotectin in preparation of fallopian tube lesion screening kit
Smith et al. Diagnosis of human Giardiasis
Zyambo et al. Reduced fractional absorption of zinc in children with environmental enteropathy in Zambia
Akinwande et al. Anthropometric indices and serum micronutrient status of helminth–infected school children from semi-urban communities in Southwestern Nigeria
JP2001521172A (en) Method for detecting oocysts of CRYPTOSPORDIUMPARVUM
CN109085355A (en) Serum protein markers combine the application in screening lung cancer and diagnosis and treatment
CN102268409B (en) Monoclonal antibody against human protein RN181 and hybridoma cell strain 3952 and kit
Omondi et al. Evaluation of Three Rapid Diagnostic Test Kits in the Diagnosis of Plasmodium Species Infections among Primary School Children in Baringo County, Kenya
EP1183540A1 (en) Methods for predicting and/or diagnosing the risk of gastric cancer
Imam et al. Serologic Evidence of Toxoplasma gondii Infection among Pregnant Females in Qassim Region, Saudi Arabia.
Dogan et al. TOXOPLASMA GONDII SEROCONVERSION DURING THE PREGNANCY IN A UNIVERSITY CLINIC FROM EASTERN PART OF TURKEY
Al Harazi et al. Missed Miscarriage Runs without Complete Evaluation: A Retrospective Study
Aziz et al. Role of circulating immune-complexes as prognostic indicators of lympho-reticular and mesenchymal malignancies in children
Test Bowel Health Test
Dawood et al. Detection of Toxoplasmosis in human and cats immunologically

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant